Small caps news round-up

ZincOx Resources has raised £300,000 at 1p a share, proceeds going to working capital and various opporunities over the next 12 months using its metallurgical expertise. It is working with EETAC, a consortium of US and international investors, which is examining the possibility of b

Imperial Innovations celebrated success at one of its investee companies on Friday, noting the announcement from Cell Medica of an exclusive licensing agreement and co-development partnership with the Baylor College of Medicineto create next-generation cellular immunotherapy products for the treatment of cancer. The AIM-traded firm said Cell Medica is a cellular immunotherapy company, focused on the development, manufacture and marketing of cell-based therapeutics for the treatment of cancers and infectious disease.

The future of CDialogues was hanging in the balance on Friday, as the AIM-traded company announced it has received a notice of termination from Numbase in respect of the four contracts from which it generates all of its current revenues. CDialogues’ board said it has historically provided its services and received its revenues pursuant to agreements entered into with local partners such as Numbase, rather than directly with the underlying mobile network operators.

Generic pharmaceutical manufacturer Beximco announced on Friday that it has commenced the export of pharmaceuticals to Kuwait. The AIM-traded firm said it marks the first time a Bangladeshi pharmaceutical company has launched products in any Gulf member country under the Gulf Cooperation Council.

Domain name sales platform business CentralNic announced on Friday that it has contracted withUK Creative Ideas - the rightsholder for the new top-level domain .art - to be its exclusive registry service provider. The AIM-traded firm said .art will be introduced in a staged launch over the next 12 months, providing the “art community and the $68bn art market” with its own exclusive designation on the internet.

Currency manager Record Plc has booked a lower full year pre-tax profit after implementing a firm-wide pay hike of 10%, also flagging the potential of a special dividend for shareholders going forward. The results -- set against a challenging backdrop of hesitant global economic growth and uncertainty in financial markets -- saw revenue at £21.13m, from £21.06m.

Shares in drug developer Scancell Holdings plunged almost 17% after it suspending dosing with current clinical trial supplies of SCIB1 for melanoma with immediate effect. Patients would be notified as soon as possible.

Lansdowne Oil & Gas has shelved its formal sale process after announcing a new deal to raise £2.1m in capital against the backdrop of a "rising oil price environment that now seems to be taking hold". The cash will be used to meet the company's share of a $7m settlement to oilfield services firm Transocean in a dispute over drilling costs dating back to 2012 and fund on-going working capital requirements until mid-2017, Lansdowne said in a statement.